Methods: This observational, prospective case series included 30 patients with age-related macular degeneration (ARMD), 24 patients with diabetic macular edema (DME) and 30 control cases. All participants received intravitreal injections of 0.5 mg ranibizumab in ARMD and DME groups, but control groups participants were not given intravitreal injections. Cardiac ischemic parameters including total creatinine kinase, creatinine kinase-MB and endothelial function measured with fl ow-mediated dilatation of the brachial artery with two-dimensional and Doppler ultrasonography were evaluated before and 1day and 1 month after the injection.

Results: Mean age of the ARMD patients was 67.80±5.67, DME was 65.42±7.12, control group was 67.33±5.70 (p:0.431). LDH, AST and ALT values were found lower at 30th day after injection in DME group. Myoglobin values were found lower at post-injection period in ARMD group. Ranibizumab is observed to have affected LDH, AST, ALT and miyoglobin. Despite the statistically signifi cant FMD values in ARMD and DME groups, percentage FMD values showed no statistically signifi cant differences.

Conclusions: Besides its antianjiogenic action, ranibizumab was shown to display distinct effects on endothelial cells in in-vitro studies. On the contrary, we did not observe any signifi cant change in vascular endothelial function. Furthermore, knowledge of the effect of ranibizumab on cardiovascular system was generally recruited from the retrospective studies. So our prospective study confi rms that intravitreal injections of ranibizumab were not associated with signifi cant risks of myocardial ischemia. Keywords : Ranibizumab, Cardiac Ischemia, Vascular Endothelial Function